|
WO2014089495A1
(en)
|
2012-12-07 |
2014-06-12 |
Chemocentryx, Inc. |
Diazole lactams
|
|
MA40132B1
(fr)
|
2014-09-11 |
2019-04-30 |
Bristol Myers Squibb Co |
Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
*
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CN107207379B
(zh)
|
2014-11-25 |
2021-08-10 |
百时美施贵宝公司 |
用于生物制品的18f-放射性标记的方法和组合物
|
|
EP3224277B1
(en)
|
2014-11-25 |
2020-08-26 |
Bristol-Myers Squibb Company |
Novel pd-l1 binding polypeptides for imaging
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
SI3297438T1
(sl)
|
2015-05-21 |
2022-03-31 |
Chemocentryx, Inc. |
CCR2 modulatorji
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10358463B2
(en)
*
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
PL3439653T3
(pl)
|
2016-04-07 |
2021-07-05 |
Chemocentryx, Inc. |
Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
MX2018014028A
(es)
*
|
2016-05-19 |
2019-04-04 |
Squibb Bristol Myers Co |
Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
KR102397783B1
(ko)
*
|
2016-06-01 |
2022-05-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-l1 결합 폴리펩티드에 의한 pet 영상화
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
ES2910832T3
(es)
*
|
2016-11-07 |
2022-05-13 |
Bristol Myers Squibb Co |
Inmunomoduladores
|
|
EP3548515A1
(en)
|
2016-12-01 |
2019-10-09 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
|
|
JP6971319B2
(ja)
|
2016-12-28 |
2021-11-24 |
グリーン・クロス・ラブ・セル・コーポレイション |
キメラ抗原受容体及びそれを発現するナチュラルキラー細胞
|
|
WO2018237153A1
(en)
*
|
2017-06-23 |
2018-12-27 |
Bristol-Myers Squibb Company |
Immunomodulators acting as antagonists of pd-1
|
|
EP3687525B1
(en)
|
2017-09-25 |
2025-10-29 |
ChemoCentryx, Inc. |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
|
JP7257393B2
(ja)
|
2017-10-03 |
2023-04-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
EP3712178A4
(en)
|
2017-11-14 |
2021-08-11 |
Green Cross Lab Cell Corporation |
ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
ES2991280T3
(es)
|
2018-01-08 |
2024-12-03 |
Chemocentryx Inc |
Antagonistas de CCR2 para el tratamiento del linfoma cutáneo de linfocitos T
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
CA3090199A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
|
|
WO2019152801A1
(en)
*
|
2018-02-02 |
2019-08-08 |
University Of Washington |
Caged amino acids for controlled metabolic incorporation and methods of use
|
|
CN108409830B
(zh)
*
|
2018-02-05 |
2021-04-23 |
郑州大学 |
一种人pd-1蛋白胞外段亲和环肽c8及其应用
|
|
JP7062792B2
(ja)
|
2018-02-13 |
2022-05-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
CA3091142C
(en)
|
2018-02-26 |
2023-04-11 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
EP3781556B1
(en)
|
2018-04-19 |
2025-06-18 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
CN112203688A
(zh)
|
2018-05-31 |
2021-01-08 |
小野药品工业株式会社 |
用于确定免疫检查点抑制剂的有效性的生物标志物
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
CN118221646A
(zh)
|
2018-07-13 |
2024-06-21 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
TW202446772A
(zh)
|
2018-10-11 |
2024-12-01 |
日商小野藥品工業股份有限公司 |
Ｓｔｉｎｇ促效化合物
|
|
KR102635333B1
(ko)
|
2018-10-24 |
2024-02-15 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
|
MX2021005047A
(es)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
DK3934757T3
(da)
|
2019-03-07 |
2023-04-17 |
Inst Of Organic Chemistry And Biochemistry Ascr V V I |
2'3'-cykliske dinukleotider og prodrugs deraf
|
|
AU2020231115B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US20220195046A1
(en)
|
2019-03-28 |
2022-06-23 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US20220041733A1
(en)
|
2019-03-28 |
2022-02-10 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
US20220251141A1
(en)
*
|
2019-05-21 |
2022-08-11 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
PH12022550244A1
(en)
|
2019-08-05 |
2022-12-12 |
Nat Cancer Ct |
Biomarkers for determining the efficacy of immune checkpoint inhibitors
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
EP4458975A3
(en)
|
2019-09-30 |
2025-02-12 |
Gilead Sciences, Inc. |
Hbv vaccines and methods treating hbv
|
|
US20220411499A1
(en)
|
2019-11-08 |
2022-12-29 |
Bristol-Myers Squibb Company |
LAG-3 Antagonist Therapy for Melanoma
|
|
EP4069729B1
(en)
|
2019-12-06 |
2025-01-22 |
Precision BioSciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
JP2023510737A
(ja)
|
2020-01-06 |
2023-03-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤
|
|
EP4121442A1
(en)
*
|
2020-03-16 |
2023-01-25 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
AR121620A1
(es)
|
2020-03-20 |
2022-06-22 |
Gilead Sciences Inc |
Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos
|
|
CN115362166A
(zh)
|
2020-03-30 |
2022-11-18 |
百时美施贵宝公司 |
免疫调节剂
|
|
JPWO2021205631A1
(OSRAM)
|
2020-04-10 |
2021-10-14 |
|
|
|
TW202200136A
(zh)
|
2020-04-10 |
2022-01-01 |
日商小野藥品工業股份有限公司 |
癌治療方法
|
|
JP2023524813A
(ja)
*
|
2020-05-08 |
2023-06-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤
|
|
CN113754736A
(zh)
*
|
2020-06-02 |
2021-12-07 |
南京礼威生物医药有限公司 |
含酰肼结构的pd-l1环肽抑制剂
|
|
CA3193421A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
EP4204453A1
(en)
|
2020-08-31 |
2023-07-05 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
US20230381112A1
(en)
|
2020-09-22 |
2023-11-30 |
Vaccitech North America, Inc. |
Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ
|
|
EP4232019A1
(en)
|
2020-10-23 |
2023-08-30 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
US20240199701A1
(en)
*
|
2021-03-24 |
2024-06-20 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
KR20240005700A
(ko)
|
2021-03-29 |
2024-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
CN117651554A
(zh)
|
2021-06-11 |
2024-03-05 |
吉利德科学公司 |
Mcl-1抑制剂与抗癌剂的组合
|
|
WO2022261310A1
(en)
|
2021-06-11 |
2022-12-15 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-body drug conjugates
|
|
JP7686086B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN113461519A
(zh)
*
|
2021-08-12 |
2021-10-01 |
浙江泽瑞生物医药有限公司 |
一种十八烷二酸单叔丁酯-pfp的制备方法
|
|
EP4419540A1
(en)
*
|
2021-10-20 |
2024-08-28 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
WO2023122945A1
(zh)
*
|
2021-12-28 |
2023-07-06 |
知和(山东)大药厂有限公司 |
环状多肽化合物及其用途
|
|
JP2025503962A
(ja)
|
2022-01-26 |
2025-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
肝細胞がんのための併用療法
|
|
CN119546287A
(zh)
|
2022-03-17 |
2025-02-28 |
百时美施贵宝公司 |
用于提高口服生物利用度的包含沙波立沙盐和烟酰胺的药物组合物
|
|
IL315992A
(en)
|
2022-04-08 |
2024-11-01 |
Bristol Myers Squibb Co |
Identification, classification and quantification of tertiary lymphoid structures using machine learning
|
|
CN119630683A
(zh)
*
|
2022-07-15 |
2025-03-14 |
乌特勒支大学 |
抗病毒环状化合物
|
|
KR20250052397A
(ko)
|
2022-08-23 |
2025-04-18 |
오노 야꾸힝 고교 가부시키가이샤 |
이중 특이성 항체
|
|
WO2024059472A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
|
AU2023409221A1
(en)
|
2022-12-21 |
2025-06-12 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024196790A1
(en)
|
2023-03-17 |
2024-09-26 |
Bristol-Myers Squibb Company |
Pharmaceutical compositions for improving oral bioavailability
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|